Eric Van Cutsem

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 49:17-24. 2013
  2. ncbi Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:3499-506. 2012
  3. ncbi Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:2861-8. 2012
  4. ncbi Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2004-10. 2011
  5. ncbi Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 44:182-94. 2008
  6. ncbi Oral capecitabine: bridging the Atlantic divide in colon cancer treatment
    Eric Van Cutsem
    University Hospital Gasthuisberg, Department of Internal Medicine, Herestraat 49, Leuven 3000, Bellgium
    Semin Oncol 32:43-51. 2005
  7. ncbi Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
    E Van Cutsem
    University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Br J Cancer 92:1055-62. 2005
  8. ncbi The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unt, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 21:1089-108. 2007
  9. ncbi Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Colorectal Cancer 6:S60-5. 2007
  10. ncbi Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
    E Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium
    Ann Oncol 21:vi1-10. 2010

Detail Information

Publications106 found, 100 shown here

  1. ncbi Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 49:17-24. 2013
    ..To determine dose-limiting toxicities (DLTs), recommended phase II trial dose (RPTD), safety, preliminary antitumour activity and pharmacokinetics of intravenous aflibercept with irinotecan, 5-fluorouracil and leucovorin (LV5FU2)...
  2. ncbi Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:3499-506. 2012
    ....
  3. ncbi Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:2861-8. 2012
    ..This article reports clinical and pharmacokinetic (PK) data...
  4. ncbi Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2004-10. 2011
    ..PTK787/ZK 222584 (PTK/ZK) is a novel oral angiogenesis inhibitor with therapeutic potential for the treatment of solid tumors...
  5. ncbi Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 44:182-94. 2008
    ..The addition of biological agents to the optimal chemotherapy regimen may achieve further improvements in efficacy...
  6. ncbi Oral capecitabine: bridging the Atlantic divide in colon cancer treatment
    Eric Van Cutsem
    University Hospital Gasthuisberg, Department of Internal Medicine, Herestraat 49, Leuven 3000, Bellgium
    Semin Oncol 32:43-51. 2005
    ..Capecitabine has also shown promising activity and good tolerability in combination with radiotherapy in rectal cancer...
  7. ncbi Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
    E Van Cutsem
    University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Br J Cancer 92:1055-62. 2005
    ..Individual dose escalation based on patient tolerance may allow more patients to receive a higher irinotecan dose without causing additional toxicity and can be an appropriate patient management strategy...
  8. ncbi The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unt, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 21:1089-108. 2007
    ..However, their introduction also raises many new questions and challenges...
  9. ncbi Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Colorectal Cancer 6:S60-5. 2007
    ..New challenges include the development of the most optimal schedule of the EGFR inhibitors and the evaluation of their role in less advanced stages and in the preoperative treatment of liver metastases of CRC...
  10. ncbi Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
    E Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium
    Ann Oncol 21:vi1-10. 2010
    ..The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC...
  11. ncbi The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 17:vi13-8. 2006
  12. ncbi Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Oncologist 11:1010-7. 2006
    ..For reasons that are not yet clear, the tyrosine kinase inhibitors of EGFR seem less effective than their monoclonal antibody counterparts in the therapy of mCRC...
  13. ncbi Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    Eric Van Cutsem
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2011-9. 2011
    ..An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken...
  14. ncbi Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:1658-64. 2007
    ..We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy...
  15. ncbi Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    E Van Cutsem
    University Hospital Gasthuisberg, Department of Internal Medicine, Leuven, Belgium
    Eur J Cancer 35:54-9. 1999
    ..The toxicity profile of CPT-11 is becoming better understood and has been considerably improved...
  16. ncbi Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 20:1842-7. 2009
    ..The Bevacizumab Expanded Access Trial (BEAT) evaluated the safety and efficacy of bevacizumab plus first-line chemotherapy in a general cohort of patients with mCRC...
  17. ncbi Systemic treatment of pancreatic cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Gastroenterol Hepatol 16:265-74. 2004
    ..The systematic evaluation of new drugs in well designed clinical trials and the search for new molecular targets for treatment are crucial in our aim to improve the outcome for patients with pancreatic cancer...
  18. ncbi Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
    E Van Cutsem
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 18:1337-45. 2000
    ..To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III...
  19. ncbi Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study
    E Van Cutsem
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 19:4097-106. 2001
    ....
  20. ncbi A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 19:332-9. 2008
    ..This trial of patients with metastatic CRC (MCRC) examined the safety, maximum tolerated dose (MTD) and pharmacokinetics (PK) of erlotinib in combination with capecitabine and oxaliplatin (XELOX), a regimen with established efficacy...
  21. ncbi The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 19:vi1-8. 2008
    ..Health care workers involved in the care of rectal cancer patients should be encouraged to adopt quality control processes leading to increased expertise...
  22. ncbi Raltitrexed: current clinical status and future directions
    E Van Cutsem
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 13:513-22. 2002
    ..Of particular interest is the combination of raltitrexed and oxaliplatin, which has shown promising antitumour effects in first-line treatment of advanced CRC and malignant mesothelioma, a disease that is refractory to chemotherapy...
  23. ncbi Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
    E Van Cutsem
    Department Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Eur J Cancer 38:1429-36. 2002
    ....
  24. ncbi Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg Leuven, Digestive Oncology Unit, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Oncol 27:2231-7. 2009
    ..Phase II results for bevacizumab plus gemcitabine provided the rationale for a phase III trial of gemcitabine-erlotinib plus bevacizumab or placebo...
  25. ncbi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  26. ncbi Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004
    ..Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy...
  27. ncbi Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
    E Van Cutsem
    Department Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 22:1430-8. 2004
    ....
  28. ncbi The treatment of advanced gastric cancer: new findings on the activity of the taxanes
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Oncologist 9:9-15. 2004
    ..This study underscores the importance of developing new therapeutic options for patients with advanced gastric cancer...
  29. ncbi Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg Leuven, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 27:3117-25. 2009
    ..CONCLUSION Irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival in patients with stage III colon cancer compared with LV5FU2 alone...
  30. ncbi The causes and consequences of cancer-associated malnutrition
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Eur J Oncol Nurs 9:S51-63. 2005
    ..Nutritional support, addressing the specific needs of this patient group, is required to help improve prognosis, and reduce the consequences of cancer-associated nutritional decline...
  31. ncbi PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
    Hans Prenen
    Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Cancer Res 15:3184-8. 2009
    ..Other mechanisms of resistance to EGFR inhibitors could involve activating mutations of the other main EGFR effector pathway, i.e., the PI3K/PTEN/AKT pathway...
  32. ncbi Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
    Bart Jacobs
    Department of Pathology, Digestive Oncology Unit, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 27:5068-74. 2009
    ....
  33. ncbi A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma
    Tom Budiharto
    Department of Radiotherapy, University Hospitals Leuven, Leuven, Belgium
    Radiat Oncol 3:30. 2008
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD) of escalating doses of radiotherapy (RT) concomitantly with a fixed dose of gemcitabine (300 mg/m2/week) within the same overall treatment time...
  34. ncbi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  35. ncbi Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome
    Albert M Wolthuis
    Department of Abdominal Surgery, University Hospital Gasthuisberg, Leuven, Belgium
    Ann Surg Oncol 19:2833-41. 2012
    ..However, tumor regression is variable. This study aimed to evaluate whether the interval between neoadjuvant therapy and surgery had an impact on pathologic response and on surgical and oncologic outcome...
  36. ncbi Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results
    Maarten Lambrecht
    Department of Radiation Oncology, UZ Gasthuisberg, Leuven, Belgium
    Int J Radiat Oncol Biol Phys 82:863-70. 2012
    ..To evaluate diffusion-weighted magnetic resonance imaging (DWI) for response prediction before and response assessment during and early after preoperative radiochemotherapy (RCT) for locally advanced rectal cancer (LARC)...
  37. ncbi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  38. ncbi Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation
    Albert M Wolthuis
    Department of Abdominal Surgery, University Hospital Gasthuisberg, Leuven, Belgium
    Ann Surg Oncol 18:684-90. 2011
    ..Tumor regression is variable, and this study was designed to evaluate the pathological response and impact on long-term disease control in responders and nonresponders...
  39. ncbi Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium B 3000
    J Clin Oncol 30:3570-7. 2012
    ..We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment...
  40. ncbi The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study
    Daphne Hompes
    Department of Abdominal Surgery, University Hospitals Gasthuisberg, and I BioStat, Katholieke Universiteit Leuven, Leuven, Belgium
    Ann Surg Oncol 19:2186-94. 2012
    ..Oxaliplatin is effective for treating advanced CRC. This study assesses the safety and efficacy of CCRS with HIPEC with oxaliplatin for patients with PC of CRC...
  41. ncbi Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
    Marc Peeters
    Department of Hepatogastroenterology, Digestive Oncology Unit, Ghent University Hospital, Ghent, Belgium
    Cancer 115:1544-54. 2009
    ....
  42. ncbi Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors
    Baki Topal
    Department of Abdominal Surgery, University Hospitals Leuven KUL, Herestraat 49, 3000 Leuven, Belgium
    Surg Endosc 26:2288-98. 2012
    ..Few reports exist on long-term survival after minimally invasive liver surgery (MILS) for colorectal liver metastases (CRLM). No data are available assessing prognostic factors in the era of current modern treatment strategies...
  43. ncbi Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study
    Genevieve Michils
    Center for Human Genetics, University Hospital Leuven, Leuven, Belgium
    Hum Mutat 25:125-34. 2005
    ..In this article, we have included an overview of genomic rearrangements in the 5q21 region...
  44. ncbi VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
    Diether Lambrechts
    Laboratory of Translational Genetics, Vesalius Research Center, VIB and KULeuven, Leuven, Belgium
    Lancet Oncol 13:724-33. 2012
    ..We assessed whether genetic variants in the VEGF pathway could act as biomarkers for bevacizumab treatment outcome...
  45. ncbi The treatment of advanced colorectal cancer: where are we now and where do we go?
    Eric Van Cutsem
    Department of Internal Medicine and Gastroenterology, Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Best Pract Res Clin Gastroenterol 16:319-30. 2002
    ....
  46. ncbi The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer
    Maarten Lambrecht
    Department of Radiation Oncology, Leuvens Kankerinstituut, University Hospitals Leuven, Leuven, Belgium
    Acta Oncol 49:956-63. 2010
    ..To investigate the use of FDG-PET/CT before, during and after chemoradiotherapy (CRT) and diffusion-weighted magnetic resonance imaging (DW-MRI) before CRT for the prediction of pathological response (pCR) in rectal cancer patients...
  47. ncbi Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Oncologist 15:390-404. 2010
    ....
  48. ncbi Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer
    Annelies Debucquoy
    Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
    Radiother Oncol 93:273-8. 2009
    ..To assess the feasibility and efficacy of the COX-2 inhibitor celecoxib in conjunction with preoperative chemoradiation for patients with locally advanced rectal cancer in a double blind randomized phase II study...
  49. ncbi New strategies for treatment of KRAS mutant metastatic colorectal cancer
    Hans Prenen
    Department of Digestive Oncology, University Hospital Gasthuisberg Leuven, Belgium
    Clin Cancer Res 16:2921-6. 2010
    ..This testing also highlights the unmet need for new treatment options in KRAS mutant metastatic CRC. In this review we will focus on possible new treatment options for these patients...
  50. ncbi Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 24:4991-7. 2006
    ..Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer...
  51. ncbi Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:2119-27. 2012
    ..To examine the hypothesis that angiogenic markers may have predictive value for bevacizumab efficacy in gastric cancer, AVAGAST included a prospective, mandatory biomarker program...
  52. ncbi Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)
    Hilde Marsé
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Eur J Oncol Nurs 8:S16-30. 2004
    ..Consequently, oncology nurses will be assuming a more significant and pivotal role in the efficient education and support of patients during home-based therapy with capecitabine...
  53. ncbi Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, Belgium
    Eur J Cancer 42:2212-21. 2006
    ....
  54. ncbi Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies
    Ravit Geva
    Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    J Surg Oncol 102:937-45. 2010
    ..The current standard of care includes peri-operative chemotherapy and surgery. The new era of biologically targeted therapy requires an in-depth look at the possible efficacy and risks of adding these agents to the treatment protocol...
  55. ncbi Computed tomographic colonography: automated tool for polyp measurement delivering on patient risk stratification
    Didier Bielen
    Department of Radiology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium
    J Comput Assist Tomogr 32:504-10. 2008
    ..We evaluated an automated polyp size measurement tool in computed tomographic colonography for its accuracy and value for patient risk stratification...
  56. ncbi Clinical management of EGFRI dermatologic toxicities: the European perspective
    Siegfried Segaert
    Department of Dermatology, Leuven University Hospital, Leuven, Belgium
    Oncology (Williston Park) 21:22-6. 2007
    ..Emollients and topical steroids can be administered for skin dryness or eczema. Paronychia is the hardest to treat but antiseptic soaks and a corticosteroid paste can alleviate symptoms to some degree...
  57. ncbi The role of chemotherapy in the current treatment of gastric cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastric Cancer 5:17-22. 2002
    ..No particular regimen has been shown to be superior to others in this context, and there is a pressing need for the evaluation of newer agents such as the oral fluoropyrimidines, taxanes, irinotecan, and oxaliplatin...
  58. ncbi Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
    Sabine Tejpar
    Digestive Oncology Unit, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:387-94. 2007
    ..We aimed to assess the incidence, characteristics, and predictive factors of magnesium wasting during treatment with EGFR-targeting antibodies, and to study the pathophysiology of this phenomenon...
  59. ncbi Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study
    Nicola Personeni
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Cancer Res 14:5869-76. 2008
    ..The value of testing KRAS mutation status, in addition to EGFR GCN, was also explored...
  60. ncbi Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Invest New Drugs 26:483-8. 2008
    ..Vorinostat in a daily oral schedule for 14 days/3 weeks was tolerable at 200 mg bid only, and no responses were observed in this study. Most patients, however, had limited drug exposure which did not allow a reliable efficacy analysis...
  61. ncbi Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development
    Xavier Sagaert
    Department of Pathology, University Hospitals of K U Leuven, Minderbroederstraat 12, B 3000 Leuven, Belgium
    Nat Rev Gastroenterol Hepatol 7:336-46. 2010
    ....
  62. ncbi Perineal colostomy with appendicostomy as an alternative for an abdominal colostomy: symptoms, functional status, quality of life, and perceived health
    Nadia Farroni
    Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Dis Colon Rectum 50:817-24. 2007
    ..This present study was designed to compare symptoms, functional status, quality of life, and perceived health after perineal colostomy and appendicostomy with that after abdominal colostomy...
  63. ncbi Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
    Andreia Costa
    Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Target Oncol 6:227-33. 2011
    ..Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents...
  64. ncbi Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, B-3000 Leuven, Belgium
    Clin Adv Hematol Oncol 5:611-3. 2007
  65. ncbi A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma
    Hannah van Malenstein
    Department of Digestive Oncology, University Hospital Gasthuisberg, Belgium
    Clin Cancer Res 16:4278-88. 2010
    ..We hypothesized that in HCC, certain microenvironmental regions exist with a characteristic gene expression related to chronic hypoxia which would induce aggressive behavior...
  66. ncbi Acute and long-term gastrointestinal consequences of chemotherapy
    Frederic Di Fiore
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:113-24. 2009
    ..We herein review and discuss the main acute and late gastrointestinal toxicities of chemotherapy and/or radiotherapy for patients with gastrointestinal malignancies...
  67. ncbi Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
    Olga Vrieze
    Department of Radiation Oncology, University Hospital Gasthuisberg, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Radiother Oncol 73:269-75. 2004
    ..To determine the additional value of FDG-positron emission tomography (PET) to optimize delineation of the clinical target volume (CTV) in patients with advanced esophageal carcinoma...
  68. ncbi Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature
    Karel Goddeeris
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Acta Gastroenterol Belg 69:377-80. 2006
    ..The combination of cerebrospinal fluid cytology and magnetic resonance imaging has a high diagnostic accuracy. The prognosis remains poor and therefore all therapies are still palliative...
  69. ncbi Carcinoid heart disease: case and literature review
    Michiel Dumoulein
    Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
    Acta Cardiol 65:261-4. 2010
    ..However, surgical valve replacement is a therapeutic option that, although it has a significant mortality, needs to be considered in selected patients and leads to improvement in functional capacity and survival...
  70. ncbi Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD)
    Genevieve Michils
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    Eur J Hum Genet 10:505-10. 2002
    ....
  71. ncbi Molecular and genetic defects in colorectal tumorigenesis
    Sabine Tejpar
    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium
    Best Pract Res Clin Gastroenterol 16:171-85. 2002
    ..Further insight into colorectal tumorigenesis pathways can lead to the development of useful prognostic indicators and target preventive and therapeutic strategies in the management of colorectal cancer...
  72. ncbi Stool tagging applied in thin-slice multidetector computed tomography colonography
    Maarten Thomeer
    Department of Radiology, University Hospitals, Catholic University of Leuven, Leuven, Belgium
    J Comput Assist Tomogr 27:132-9. 2003
    ..To compare thin-slice multidetector computed tomography colonography (CTC) that uses stool tagging with colonoscopy...
  73. ncbi XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
    ..The present studies further characterize efficacy and safety of the XELOX regimen...
  74. ncbi Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials
    Emmanuel Mitry
    Hépato gastroentérologie et oncologie digestive, Hopital Ambroise Pare, Boulogne, France
    J Clin Oncol 26:4906-11. 2008
    ..We report here a pooled analysis based on individual data from these two trials...
  75. ncbi Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
    Hans Joachim Schmoll
    Martin Luther University, Halle, Germany
    J Clin Oncol 25:102-9. 2007
    ..To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer...
  76. ncbi Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz-Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
    ..The severity of rash was related to efficacy. Neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetuximab in this setting...
  77. ncbi Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..Overall, intratumoral phosphorylation of MAPK and Akt was not significantly inhibited by gefitinib. However, the finding that decreases in pAkt correlated with enhanced apoptosis deserves further exploration...
  78. ncbi Progress with biological agents in metastatic colorectal cancer leads to many challenges
    Eric Van Cutsem
    J Clin Oncol 24:3325-7. 2006
  79. ncbi Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells
    Sandra Van Schaeybroeck
    Department of Oncology, Centre for Cancer Research and Cell Biology, Queen s University Belfast, University Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, United Kingdom
    Mol Cancer Ther 5:1154-65. 2006
    ..These novel findings suggest that modulation of EGFR activity following drug treatment determines response to gefitinib in combination with chemotherapy in NSCLC cells...
  80. ncbi Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group
    Manfred P Lutz
    University of Ulm, Ulm, Germany
    J Clin Oncol 23:9250-6. 2005
    ..To define the efficacy and toxicity of docetaxel plus gemcitabine or docetaxel plus cisplatin for advanced pancreatic carcinoma...
  81. ncbi Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
    Eric Van Cutsem
    JAMA 294:2758-60. 2005
  82. ncbi Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Oncology 69:46-56. 2005
    ..001). Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy...
  83. ncbi Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy
    Sandra Van Schaeybroeck
    Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, North Ireland
    Clin Cancer Res 11:7480-9. 2005
    ....
  84. ncbi The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus
    Vincenzo Valentini
    Cattedra di Radioterapia, Universita Cattolica S Cuore, Rome, Italy
    Radiother Oncol 76:241-50. 2005
    ..Agreement between Experts, Centres, and specialists who participated in the Conference are reported...
  85. ncbi Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Box 426, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:5660-7. 2005
    ..We compared the overall response rate (ORR) and safety of docetaxel plus cisplatin (DC) with DC plus fluorouracil (DCF) to select either DC or DCF as the experimental treatment in the ensuing phase III part of trial V-325...
  86. ncbi The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
    Siegfried Segaert
    Department of Dermatology, Katholieke Universiteit Leuven, Belgium
    J Dtsch Dermatol Ges 3:599-606. 2005
    ..Evidence-based studies are needed to determine the best way to manage these effects...
  87. ncbi Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial
    Bernard Nordlinger
    Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris, 9 avenue Charles de Gaulle, Boulogne Billancourt Cedex 92104, France
    Lancet Oncol 6:459-68. 2005
    ..The study also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole...
  88. ncbi Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    David Cunningham
    Royal Marsden Hospital, London, United Kingdom
    N Engl J Med 351:337-45. 2004
    ..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
  89. ncbi Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastroi
    Manfred P Lutz
    Caritasklinik St Theresia, Saarbrucken, Germany
    J Clin Oncol 25:2580-5. 2007
    ....
  90. ncbi Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3205-9. 2007
    ..However, a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting...
  91. ncbi Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3210-6. 2007
    ..Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial...
  92. ncbi Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Jim Cassidy
    J Clin Oncol 26:2226-7; author reply 2228. 2008
  93. ncbi Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  94. ncbi Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
    Bernard Nordlinger
    centre hospitalier universitaire Ambroise Paré, Assistance Publique Hopitaux de Paris, Departments of Surgery and Oncology, Boulogne Billancourt, France
    Lancet 371:1007-16. 2008
    ..We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer...
  95. ncbi Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
    ..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
  96. ncbi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  97. ncbi A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia
    Bertram Wiedenmann
    Department of Internal Medicine, Charite, Humboldt University, Berlin, Germany
    J Support Oncol 6:18-25. 2008
    ..Adding infliximab to gemcitabine to treat cachexia in advanced pancreatic cancer patients was not associated with statistically significant differences in safety or efficacy when compared with placebo...
  98. ncbi Clinical research of EGFR inhibitors and related dermatologic toxicities
    Roman Perez-Soler
    Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    Oncology (Williston Park) 21:10-6. 2007
    ..Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials...
  99. ncbi Clinical presentation and pathophysiology of EGFRI dermatologic toxicities
    Edith P Mitchell
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 21:4-9. 2007
    ..Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies...
  100. ncbi Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  101. ncbi The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....